Trial Profile
A Single Centre, Randomised, Double-blind, Placebo-controlled, Four-way Cross Over Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of GSK2190915 in Healthy Japanese Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Fiboflapon (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; GSK
- 19 Oct 2010 Actual end date (Oct 2009) added as reported by ClinicalTrials.gov.
- 19 Oct 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.